Precision in production: optimizing monitoring and quality control for high-value plasmids

Plasmids are vital for producing viral vector-, mRNA-, and DNA-based therapies and vaccines. However, current development efficiencies and production capacities are insufficient to meet the growing demand. Join us as we delve into strategies to enhance the efficiency and control of plasmid production.

Quality control (QC) is paramount throughout the production process to ensure the safety, purity, and potency of the final product. Spectrophotometric analysis, particularly the 260/280 UV absorbance ratio, is commonly used to assess plasmid purity. However, traditional methods have limitations such as fixed-pathlength, which is one of essential characteristics of conventional spectrophotometers. This can introduce unnecessary risks and errors due to sample preparation and dilution requirements.

Attend this webinar for insights into the capabilities of Variable Pathlength Technology (VPT), its benefits compared to traditional UV-visible techniques and sensor equipment, and how this innovative technology enables rapid and precise real-time concentration measurement across a broad range of concentrations.

• Discover strategies for optimizing E. coli cell growth performance through the implementation of in-line, real-time OD600 (abs/mm) monitoring during the fermentation process
• Review case studies of VPT platform implementation and validation for downstream QC/at-line pDNA purity analysis
• Discover how the CTech™ SoloVPE® (at-line) and the FlowVPX® (in-line) Systems serve as essential Process Analytical Tools (PAT) for optimizing and controlling the plasmid development and production process
• Get introduced to PAT-driven in-line VPT integration for automated process control (this may or may not be RPM) and explore how other users have integrated the FlowVPX into their existing downstream UF/DF processes

Oleksandr Karpenko

Bioprocess Analytics Application Scientist at Repligen

Oleksandr Karpenko serves as a Bioprocess Analytics Field Application Scientist at Repligen Corporation, where his primary focus is ensuring that our CTech Analytical solutions meet customers’ expectations and analytical needs. Collaborating closely with bioprocess teams, Oleksandr provides scientific guidance, supports implementation, validation, and conducts training sessions on CTech™ Analytical Solutions. His expertise lies in developing and optimizing customized methods to ensure optimal usage of analytical instruments and overall customer process success.

Before joining Repligen, Oleksandr held leadership positions at both BioCape GmbH and Biotensidon GmbH. At BioCape, he led a team in synthesizing, characterizing, and scaling bio-based surfactants. Earlier, at Biotensidon, he began as a Scientist, focusing on fermentation process optimization, before advancing to Head of Bioprocess Development, overseeing the design, optimization, and scaling of bioprocesses for high-value biosurfactants and raw materials.

Oleksandr holds a Doctor of Philosophy (PhD) from Kyiv Polytechnic Institute and a Master of Science (MS) in Biotechnology from Lviv Polytechnic National University. His skills include expertise in spectroscopy, process development, downstream processing, bacterial fermentation, continuous improvement, and statistical analysis.

Oleksandr's wealth of experience has shaped him into an exceptionally knowledgeable partner who tirelessly ensures his customers achieve optimal analytical results while operating efficiently.

Watch now

SPEAKERS

Oleksandr Karpenko

Bioprocess Analytics Application Scientist at Repligen

You might also like

Process in the product: a new analytical tool for AAV production optimization and monitoring

Blaž Bakalar, Ivana Petrović Koshmak

19 November

Watch

Empowering patient care: in-process and quality control solutions for cellular therapies

Christin Tischner, Simon Lennartz

23 May

Watch

Optimizing access to high quality, standardized, and compliant leukopaks for the development and commercialization of allogeneic therapies

Makensie Becker

18 April

Watch

Scalable solutions for optimizing lentiviral vector production

Vera Ortseifen, Kathrin Teschner

11 December

in 20

Days

Register